STOCK TITAN
  1. Home
  2. Sec-filings
  3. KLRS
  4. [ARS] Kalaris Therapeutics, Inc. SEC Filing

[ARS] Kalaris Therapeutics, Inc. SEC Filing

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
ARS
Rhea-AI Filing Summary
Riscrivi il seguente testo:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세요:
Réécrivez le texte suivant :
Schreibe den folgenden Text um:
Positive
  • None.
Negative
  • None.
Riscrivi il seguente testo:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세요:
Réécrivez le texte suivant :
Schreibe den folgenden Text um:
ARS - Kalaris Therapeutics, Inc.

ARS Filing - Kalaris Therapeutics, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: Kalaris Therapeutics, Inc. (KLRS)

Acceptance Date: 2025-07-01T07:40:26.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Stock KLRS logo
Kalaris Therapeutics Inc

NASDAQ:KLRS

KLRS Rankings

#5545 Ranked by Market Cap
N/A Ranked by Dividends

KLRS Latest News

Jun 2, 2025
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
May 23, 2025
Kalaris to Participate at Stifel Ophthalmology Forum
May 14, 2025
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights
Apr 4, 2025
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
Mar 18, 2025
Kalaris Announces Closing of Merger with AlloVir

KLRS Latest SEC Filings

Jul 1, 2025
[DEFA14A] Kalaris Therapeutics, Inc. Additional Proxy Soliciting Materials
Jul 1, 2025
[DEF 14A] Kalaris Therapeutics, Inc. Definitive Proxy Statement
Jun 20, 2025
[8-K] Kalaris Therapeutics, Inc. Reports Material Event

KLRS Stock Data

46.57M
15.49M
Biological Products, (no Disgnostic Substances)
PALO ALTO